si ezh2 Search Results


sirnas targeting ezh2  (Shanghai GenePharma)
90
Shanghai GenePharma sirnas targeting ezh2
lncRNA ABHD11‐AS1 binds to <t>EZH2</t> to epigenetically repress TIMP2. A, RNA immunoprecipitation was used to detect the binding relationship between ABHD11‐AS1 and EZH2. HOTAIR and MALAT1 were used as positive controls. B, Western blot was used to examine the TIMP2 expression of after knockdown of EZH2. GAPDH was used as control. C, qRT‐PCR analysis of immunoprecipitated chromatin by H3K27me3 antibody on TIMP2 promoter. IgG served as a negative control. D, Western blot was used to detect expression of TIMP2. GAPDH was used as loading control. * P < .05, ** P < .01
Sirnas Targeting Ezh2, supplied by Shanghai GenePharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sirnas targeting ezh2/product/Shanghai GenePharma
Average 90 stars, based on 1 article reviews
sirnas targeting ezh2 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


lncRNA ABHD11‐AS1 binds to EZH2 to epigenetically repress TIMP2. A, RNA immunoprecipitation was used to detect the binding relationship between ABHD11‐AS1 and EZH2. HOTAIR and MALAT1 were used as positive controls. B, Western blot was used to examine the TIMP2 expression of after knockdown of EZH2. GAPDH was used as control. C, qRT‐PCR analysis of immunoprecipitated chromatin by H3K27me3 antibody on TIMP2 promoter. IgG served as a negative control. D, Western blot was used to detect expression of TIMP2. GAPDH was used as loading control. * P < .05, ** P < .01

Journal: Cancer Medicine

Article Title: lncRNA ABHD11‐AS1, regulated by the EGFR pathway, contributes to the ovarian cancer tumorigenesis by epigenetically suppressing TIMP2

doi: 10.1002/cam4.2586

Figure Lengend Snippet: lncRNA ABHD11‐AS1 binds to EZH2 to epigenetically repress TIMP2. A, RNA immunoprecipitation was used to detect the binding relationship between ABHD11‐AS1 and EZH2. HOTAIR and MALAT1 were used as positive controls. B, Western blot was used to examine the TIMP2 expression of after knockdown of EZH2. GAPDH was used as control. C, qRT‐PCR analysis of immunoprecipitated chromatin by H3K27me3 antibody on TIMP2 promoter. IgG served as a negative control. D, Western blot was used to detect expression of TIMP2. GAPDH was used as loading control. * P < .05, ** P < .01

Article Snippet: EZH2 was silenced with siRNAs targeting EZH2 or scrambled siRNA control (purchased from GenePharma).

Techniques: RNA Immunoprecipitation, Binding Assay, Western Blot, Expressing, Knockdown, Control, Quantitative RT-PCR, Immunoprecipitation, Negative Control

EGFR regulated‐ABHD11‐AS1 in the progression of ovarian cancer progress in vivo. A, Comparison of tumor sizes between groups treated with Gefitinib, with shABHD11‐AS1, and no treatment. B, Tumor growth curve for groups treated with Gefitinib, with shABHD11‐AS1, and no treatment. C, Tumor weight for groups treated with Gefitinib, with shABHD11‐AS1, and no treatment. D, Immunohistochemistry was used to detect expression of EZH2 in groups treated with Gefitinib, with shABHD11‐AS1, and no treatment. Scale bar, 300 μm. E, qRT‐PCR was used to examine the expression of ABHD11‐AS1 and EZH2 in groups treated with Gefitinib, with shABHD11‐AS1, and no treatment. F, Western blot was used to detect the expression of EZH2 and TIMP2 in groups treated with Gefitinib, with shABHD11‐AS1, and no treatment. GAPDH was served as loading control. * P < .05, ** P < .01

Journal: Cancer Medicine

Article Title: lncRNA ABHD11‐AS1, regulated by the EGFR pathway, contributes to the ovarian cancer tumorigenesis by epigenetically suppressing TIMP2

doi: 10.1002/cam4.2586

Figure Lengend Snippet: EGFR regulated‐ABHD11‐AS1 in the progression of ovarian cancer progress in vivo. A, Comparison of tumor sizes between groups treated with Gefitinib, with shABHD11‐AS1, and no treatment. B, Tumor growth curve for groups treated with Gefitinib, with shABHD11‐AS1, and no treatment. C, Tumor weight for groups treated with Gefitinib, with shABHD11‐AS1, and no treatment. D, Immunohistochemistry was used to detect expression of EZH2 in groups treated with Gefitinib, with shABHD11‐AS1, and no treatment. Scale bar, 300 μm. E, qRT‐PCR was used to examine the expression of ABHD11‐AS1 and EZH2 in groups treated with Gefitinib, with shABHD11‐AS1, and no treatment. F, Western blot was used to detect the expression of EZH2 and TIMP2 in groups treated with Gefitinib, with shABHD11‐AS1, and no treatment. GAPDH was served as loading control. * P < .05, ** P < .01

Article Snippet: EZH2 was silenced with siRNAs targeting EZH2 or scrambled siRNA control (purchased from GenePharma).

Techniques: In Vivo, Comparison, Immunohistochemistry, Expressing, Quantitative RT-PCR, Western Blot, Control